This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TEM vs. BFLY: Which Stock Offers Greater Upside Amid Health Tech Boom?
by Sridatri Sarkar
Tempus AI posts its first positive adjusted EBITDA while Butterfly Network pushes revenue gains and efficiency in a rapidly evolving health tech market.
How Did Tempus AI Power Its Move to Positive EBITDA in Q3?
by Sridatri Sarkar
TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.
TEM Continues to Strengthen Its Genomics Leadership With New Products
by Sridatri Sarkar
Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.
Should You Buy, Hold or Sell TEM Stock Post Q3 Earnings Release?
by Sridatri Sarkar
Tempus AI posts first positive adjusted EBITDA and 84.7% revenue surge, signaling new growth momentum amid premium valuation.
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
by Debanjana Dey
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours
by Zacks Equity Research
Tempus AI reports a narrower-than-expected Q3 loss and stronger revenues, raises full-year outlook, but shares decline following the results.
Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tempus (TEM) delivered earnings and revenue surprises of +31.25% and +2.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of +41.67% and +5.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
TEM vs. EXAS: Which Genomics Player Offers Greater Upside?
by Sridatri Sarkar
Tempus AI's soaring genomics revenues and Exact Sciences' diagnostic breakthroughs spotlight two distinct routes to precision oncology growth.